The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.
18F-FDG
68Ga-labeled somatostatin analogue
NET
PRRT
RECIST
SWOG
WHO
neuroendocrine tumors
peptide receptor radionuclide therapy
response assessment
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
12 Dec 2020
12 Dec 2020
Historique:
received:
16
11
2020
revised:
09
12
2020
accepted:
09
12
2020
entrez:
16
12
2020
pubmed:
17
12
2020
medline:
17
12
2020
Statut:
epublish
Résumé
The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owed to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT.
Identifiants
pubmed: 33322819
pii: diagnostics10121083
doi: 10.3390/diagnostics10121083
pmc: PMC7763988
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lancet. 2011 Dec 10;378(9808):2005-2012
pubmed: 22119496
J Nucl Med. 2018 Jul;59(7):1085-1091
pubmed: 29572257
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):895-906
pubmed: 31838581
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1336-1344
pubmed: 30566620
Mol Imaging Biol. 2017 Jun;19(3):437-445
pubmed: 27743210
Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):881-8
pubmed: 23443937
Lancet Oncol. 2015 Sep;16(9):e435-e446
pubmed: 26370353
Endocr Relat Cancer. 2020 Mar;27(3):R67-R77
pubmed: 31846429
Endocr Metab Immune Disord Drug Targets. 2018;18(5):419-449
pubmed: 29237387
Curr Radiopharm. 2019;12(1):11-22
pubmed: 30539709
J Nucl Med Technol. 2011 Dec;39(4):317-24
pubmed: 22068564
Q J Nucl Med Mol Imaging. 2018 Jun;62(2):129-139
pubmed: 29166754
Nature. 2017 Mar 2;543(7643):65-71
pubmed: 28199314
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
J Nucl Med. 2019 Jul;60(7):937-943
pubmed: 31263080
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
J Clin Endocrinol Metab. 2011 Dec;96(12):3741-9
pubmed: 21994954
J Clin Oncol. 2005 Apr 20;23(12):2754-62
pubmed: 15837990
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Cancer. 1981 Jan 1;47(1):207-14
pubmed: 7459811
Eur Radiol. 2015 Mar;25(3):751-9
pubmed: 25447971
Clin Nucl Med. 2012 Jun;37(6):e141-7
pubmed: 22614212
Curr Radiopharm. 2018;11(3):200-208
pubmed: 29732998
Clin Pharmacol Ther. 2001 Mar;69(3):89-95
pubmed: 11240971
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490-499
pubmed: 27704193
World J Clin Oncol. 2020 Sep 24;11(9):723-731
pubmed: 33033694
Neuroendocrinology. 2019;108(3):219-231
pubmed: 30654372
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
BMC Cancer. 2020 Apr 16;20(1):326
pubmed: 32299391
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Eur J Nucl Med. 2000 Mar;27(3):273-82
pubmed: 10774879
Mol Imaging Biol. 2019 Jun;21(3):582-590
pubmed: 30014345
EJNMMI Res. 2018 Aug 29;8(1):89
pubmed: 30159614
J Nucl Med. 2010 Sep;51(9):1349-56
pubmed: 20720050
Nucl Med Commun. 2020 Apr;41(4):363-369
pubmed: 31977752
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):38-46
pubmed: 28864881
Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):28-37
pubmed: 26627724
J Clin Med. 2019 Jul 13;8(7):
pubmed: 31337043
J Mol Med (Berl). 2017 Nov;95(11):1167-1178
pubmed: 28871446
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137
pubmed: 31254038
Mol Imaging Biol. 2015 Jun;17(3):313-8
pubmed: 25319765
Radiother Oncol. 2019 Dec;141:108-115
pubmed: 31542317
J Clin Endocrinol Metab. 2015 Nov;100(11):E1437-45
pubmed: 26348352
Eur Radiol Exp. 2020 Feb 7;4(1):11
pubmed: 32034573
Endocrinol Metab Clin North Am. 2011 Mar;40(1):111-34, viii
pubmed: 21349414
Oncotarget. 2017 Jan 24;8(4):7039-7049
pubmed: 27705948
Diagnostics (Basel). 2020 Aug 16;10(8):
pubmed: 32824388
Cancer Treat Rev. 2009 Jun;35(4):309-21
pubmed: 19136215
Curr Radiopharm. 2011 Oct;4(4):306-20
pubmed: 22202153
Radiology. 2006 Nov;241(2):441-8
pubmed: 16982815
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):5-19
pubmed: 25273832
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Invest New Drugs. 1992 Nov;10(4):239-53
pubmed: 1487397
Eur Radiol. 2013 Nov;23(11):3029-39
pubmed: 23793519
Neuroendocrinology. 2020;110(7-8):662-670
pubmed: 31597134
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):262-277
pubmed: 28894897
PLoS One. 2013 May 15;8(5):e63364
pubmed: 23691035
Diagn Interv Imaging. 2014 Mar;95(3):289-300
pubmed: 24034971
Br J Radiol. 2018 Nov;91(1091):20180108
pubmed: 30102557
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1083-1089
pubmed: 29395627
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1490-1500
pubmed: 28361189
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1238-46
pubmed: 25808630
J Clin Oncol. 2016 Nov 10;34(32):3906-3913
pubmed: 27621394
Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):2004-10
pubmed: 20596866
Lancet. 1989 Feb 4;1(8632):242-4
pubmed: 2563413
Cancer Imaging. 2020 Aug 10;20(1):57
pubmed: 32778165
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):505-10
pubmed: 24196919
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624
pubmed: 28428192
Ann Surg Oncol. 2010 Sep;17(9):2427-43
pubmed: 20217257
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16
pubmed: 23389427
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Clin Oncol. 2007 May 1;25(13):1753-9
pubmed: 17470865
Acta Oncol. 1993;32(2):167-70
pubmed: 8391830
Contrast Media Mol Imaging. 2019 Nov 11;2019:1517208
pubmed: 31787860
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):212-25
pubmed: 19727718
Nucl Med Commun. 2016 Oct;37(10):1030-7
pubmed: 27243215
World J Nucl Med. 2019 Dec 18;18(4):389-395
pubmed: 31933555
Ann Oncol. 2020 Feb;31(2):202-212
pubmed: 31959337
J Thorac Oncol. 2019 Sep;14(9):1651-1661
pubmed: 31085341
J Nucl Med. 2014 Feb;55(2):183-90
pubmed: 24434296
Clin Cancer Res. 2010 Feb 1;16(3):978-85
pubmed: 20103666
Neuroendocrinology. 2016;103(5):452-9
pubmed: 26337010
Front Endocrinol (Lausanne). 2018 Dec 04;9:740
pubmed: 30564197
J Nucl Med. 2017 Sep;58(Suppl 2):91S-96S
pubmed: 28864619
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169
pubmed: 29484451
J Nucl Med. 2015 Feb;56(2):177-82
pubmed: 25593115
J Nucl Med. 2020 Apr;61(4):488-495
pubmed: 32060219
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601
pubmed: 28547177
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1143-1158
pubmed: 30170872
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Clin Cancer Res. 2018 May 1;24(9):2182-2193
pubmed: 29440175
J Nucl Med. 2019 Mar;60(3):377-385
pubmed: 30115686
J Clin Endocrinol Metab. 2019 Feb 1;104(2):285-292
pubmed: 30219888
Oncotarget. 2018 Sep 4;9(69):33059
pubmed: 30237849
J Nucl Med. 2009 Sep;50(9):1427-34
pubmed: 19690033
Front Oncol. 2020 Feb 21;10:193
pubmed: 32154181
Endocr Connect. 2019 Mar 1;:
pubmed: 30865931
Gastroenterology. 2018 Mar;154(4):998-1008.e1
pubmed: 29155309
Lancet Oncol. 2008 Jan;9(1):61-72
pubmed: 18177818
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2638-2655
pubmed: 31240330
Eur J Cancer Care (Engl). 2013 Nov;22(6):714-25
pubmed: 23895457
Cancer J. 2016 Nov/Dec;22(6):418-422
pubmed: 27870685
Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):724
pubmed: 15551131
Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1770-80
pubmed: 23873003
Nature. 2015 Apr 30;520(7549):609-11
pubmed: 25925459
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1441-8
pubmed: 20461371
Virchows Arch. 2002 May;440(5):461-75
pubmed: 12021920
Nat Rev Endocrinol. 2018 Nov;14(11):656-669
pubmed: 30158549
J Nucl Med. 2013 Oct;54(10):1689-96
pubmed: 24084705
Theranostics. 2017 Mar 1;7(5):1149-1158
pubmed: 28435454
Future Oncol. 2018 Jan;14(2):111-122
pubmed: 29072093
Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):311-331
pubmed: 30510849
Endocr Pathol. 2018 Jun;29(2):150-168
pubmed: 29520563
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Eur J Nucl Med Mol Imaging. 2014 May;41(5):925-33
pubmed: 24504504
N Engl J Med. 1986 May 1;314(18):1145-51
pubmed: 3007986
Radiology. 2012 Apr;263(1):139-48
pubmed: 22344403
Endocr Relat Cancer. 2015 Aug;22(4):561-75
pubmed: 26037279
Indian J Pathol Microbiol. 2020 Jan-Mar;63(1):98-99
pubmed: 32031132
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2244-2251
pubmed: 31350603
Nucl Med Commun. 2016 Aug;37(8):874-81
pubmed: 27096719
J Nucl Med. 2005 Jan;46 Suppl 1:92S-8S
pubmed: 15653657
Neuroendocrinology. 2012;96(4):261-71
pubmed: 22907438
Curr Opin HIV AIDS. 2010 Nov;5(6):463-6
pubmed: 20978388
Eur J Nucl Med Mol Imaging. 2016 May;43(5):839-851
pubmed: 26596723
Eur J Radiol. 2015 Aug;84(8):1436-1443
pubmed: 26022520
Endocr Connect. 2016 Sep;5(5):174-87
pubmed: 27582247
Neuroendocrinology. 2017 Mar 30;105(3):212-244
pubmed: 28355596
Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73
pubmed: 19995807
J Nucl Med. 2018 Oct;59(10):1566-1573
pubmed: 30042164
Nucl Med Commun. 2020 Jul;41(7):601-617
pubmed: 32404645
J Nucl Med. 2014 Feb;55(2):204-10
pubmed: 24379222
J Nucl Med. 2020 Jul;61(7):1014-1020
pubmed: 31806775
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Radiother Oncol. 2018 Jun;127(3):349-360
pubmed: 29779918
Oncotarget. 2018 Feb 15;9(24):16932-16950
pubmed: 29682195
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
Oncologist. 2019 Jun;24(6):783-790
pubmed: 30158287
PLoS One. 2015 Apr 20;10(4):e0124884
pubmed: 25894842
Nucl Med Mol Imaging. 2019 Feb;53(1):14-29
pubmed: 30828395